STAT
APRIL 10, 2024
stood at 323 during the fourth quarter of last year — the highest figure reached since such data began being tracked in 2001 — underscoring growing concerns about patient harm across the country. The number of ongoing and active drug shortages in the U.S.
STAT
APRIL 11, 2024
stood at 323 during the fourth quarter of last year — the highest figure reached since such data began being tracked in 2001 — underscoring growing concerns about patient harm across the country, STAT tells us. Unresolved The number of ongoing and active drug shortages in the U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
DECEMBER 9, 2024
No immune cell-associated neurotoxicity syndrome (ICANS) was observed. This innovative design can increase binding to tumour cells while minimising on-target, off-tumour side effects and/or boost immune cell activity against tumour cells by triggering multiple signals. The median duration of CRS was 2 days (range: 18).
European Pharmaceutical Review
DECEMBER 12, 2023
He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.
pharmaphorum
MARCH 9, 2021
SARS-CoV-2 is likely to stay endemic in the human population for the foreseeable future, ExeVir noted, with variants capable of evading immunity the most likely cause of the disease in the future as global vaccination programmes begin to take effect. ExeVir is not the first company to spin out of VIB to focus on camelid antibodies.
NY Times
DECEMBER 2, 2021
In 2001, U.N. estimates suggested 150 million people would be infected with H.I.V. That preceded an ambitious global campaign to curb the virus. How well did it work?
pharmaphorum
SEPTEMBER 13, 2022
Crucially, he observed a connection between certain tumours and inflammation, noting that neoplastic tissues were often covered with leukocytes of the immune system. 2001– FDA green lights revolutionary treatments. Virchow was the first to argue that cancer derives from changes in normal cells. 1907 – The magic bullet of immunotherapy.
Expert insights. Personalized for you.
343 
Let's personalize your content